Parteck® SRP 80
New functional excipient for sustained drug release

• Press release - 26 October 2015
  
  

For a drug therapy to succeed, the patient must fully comply with treatment. That's one of the reasons why solid oral drug formulations are so widely used. For many treatments, controlled and long-acting release of the APIs (active pharmaceutical ingredients) is required.

For every API there is a minimum effective dose and a maximum tolerated dose – between which is the so-called "therapeutic window." It is critical to stay within this window by controlling the release of the API from the tablet, because otherwise the effectiveness of the drug can be compromised or toxic effects can occur. A long-acting API release can help increase patient compliance by reducing dose frequency.
For these reasons our Parteck® SRP 80 excipient has been specifically designed for controlled-release solid oral formulations with superior reliability and consistency.

"Pharmaceutical excipients play an essential role in the development of safe and effective medicines. Parteck® SRP 80 represents a new choice for customers looking to formulate prolonged-release oral dosage forms with reliable performance profiles as well as robust and cost-efficient production processes – which can translate to improved patient safety and compliance."  
— Andrew Bulpin, Executive Vice President, Process Solutions, Merck

Parteck® SRP 80 is the newest addition to our Parteck® functional excipients portfolio, specifically created for solid dose formulations. It can help our customers accelerate their formulation work – from simplified feasibility and development to rapid and cost-efficient manufacturing.

Selected features and benefits of Parteck® SRP 80:

Features	Benefits
Suitable for direct compression processes	Simplified development and manufacturing
Constant API release over broad pH range	No pH-induced dose dumping (shown in-vitro)
Synthetically derived	No performance or quality variability in contrast to naturally derived raw materials